BioCryst begins phase 1 trial with BCX9250 for treatment of fibrodysplasia ossificans progressiva

This article was originally published here

The Phase 1 trial will evaluate single and multiple ascending doses of oral BCX9250 in healthy volunteers. The company expects to report the results from the trial in

The post BioCryst begins phase 1 trial with BCX9250 for treatment of fibrodysplasia ossificans progressiva appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply